Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short Side

Sunesis Pharmaceuticals is nearing a binary event with the top-line data readout of its Phase 3 Valor trial that is expected any day now.

http://ift.tt/1qwMX35